arrow
R

Ryunosuke Machida

japan clinical oncology group
H指数:15
被引数:1,371

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Definitive IMRT alone with reduced prophylactic nodal irradiation for Early-Stage Oropharyngeal Cancer: JCOG1208

早期口咽癌采用明确的IMRT单放联合缩小的预防性淋巴结照射:JCOG1208

2026-06-280
OA
Radiofrequency Ablation for Early Stage Breast Cancer as a Potential Alternative to Partial Mastectomy: 5-Year Results from the Multiple-Center, Single-Arm, Phase 3 RAFAELO Study (NCCH1409)

射频消融作为早期乳腺癌保乳手术的潜在替代方案:多中心、单臂、III期RAFAELO研究(NCCH1409)的5年结果

2026-02-180
PRE
A randomized controlled trial of metastasis-directed therapy for oligometastases in breast cancer: OLIGAMI trial (JCOG2110)

乳腺癌寡转移的转移导向疗法随机对照试验:OLIGAMI试验(JCOG2110)

2026-01-010
PRE
RESULTS OF A MULTICENTER PHASE 2 BASKET TRIAL EVALUATING THE EFFICACY OF TASURGRATINIB (E7090) IN PATIENTS WITH ADVANCED SOLID TUMORS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) GENE ALTERATION, INCLUDING THOSE WITH PRIMARY BRAIN TUMORS: FORTUNE STUDY

评估TASURGRATINIB(E7090)在具有成纤维细胞生长因子受体(FGFR)基因变异的晚期实体瘤患者(包括原发性脑肿瘤患者)中的疗效的多中心II期篮式试验结果:FORTUNE研究

2025-11-010
OAAI
Thoracoscopic versus open oesophagectomy for patients with oesophageal cancer (JCOG1409 MONET): a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial

胸腔镜与开胸食管切除术治疗食管癌患者(JCOG1409 MONET):一项多中心、开放标签、随机对照、III期、非劣效性试验

2025-10-130
PRE
Facial Skin With Conspicuous Enlarged Pores Closely Related to Severity of Facial Acneiform Rash and Therapeutic Effects of EGFR Inhibitors in RAS Wild-Type Metastatic Colorectal Cancer: Ancillary Analysis of FAEISS Study (NCCH1512)

面部皮肤显著扩大毛孔与面部痤疮样皮疹严重程度及EGFR抑制剂在RAS野生型转移性结直肠癌中的治疗效果密切相关:FAEISS研究(NCCH1512)的附加分析

2025-06-120
OA
Postoperative Recurrence Pattern of Clinical Stage I Esophageal Cancer After Esophagectomy with Two- or Three-Field Lymph Node Dissection: Supplementary Analysis from JCOG0502

临床期I食管癌行二野或三野淋巴结清扫术食管切除术后的术后复发模式:JCOG0502研究的补充分析

2025-05-090
PRE
Prognostic Impact of Thoracic Duct Resection in Patients Who Underwent Transthoracic Esophagectomy Following Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma: Exploratory Analysis of JCOG1109
2024-10-071
PRE
A Randomized Controlled Trial of Metastasisdirected Therapy for Oligometastases in Breast Cancer (OLIGAMI trial; JCOG2110)
2024-05-020
PRE
Genomic landscape of circulating tumor DNA in cervical cancer in Asia: NCCH1905/A-TRAIN trial
2024-03-220
PRE
Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy - a supplementary analysis of JCOG0601

利妥昔单抗联合CHOP治疗弥漫性大b细胞淋巴瘤患者的继发性中枢神经系统受累-JCOG0601的补充分析

2024-01-271
OAAI
Long-Term Follow-up of a Randomized Controlled Trial on Accelerated Radiation Therapy Versus Standard Fractionated Radiation Therapy for Early Glottic Cancer (JCOG0701A3)

加速放疗与标准分次放疗治疗早期声门型喉癌随机对照试验的长期随访 (JCOG0701A3)

2023-12-013
OAAI
Novel approach of prophylactic radiation to reduce toxicities comparing 2-step40 with 56-Gy simultaneous integrated boost intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the head and neck, an intergroup phase III trial (JCOG1912, NEW BRIDGE)
2023-11-060
OAAI
Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)

daratumumab (D) 与硼替佐米加D作为老年或非老年患者拒绝接受未经治疗的多发性骨髓瘤移植的d-mpb后维持治疗的随机III期研究 (JCOG1911,b-dash研究)

2023-11-010
PRE
Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib

第二步研究方案,日本临床肿瘤学组研究JCOG1802: 晚期软组织肉瘤二线治疗的随机II期试验,比较小梁肽,艾日布林和帕唑帕尼

2023-03-081
OAAI